

Title (en)
BENZIMIDAZOLONE DERIVATIVES

Title (de)
BENZIMIDAZOLONDERIVATE

Title (fr)
DERIVES DE BENZIMIDAZOLONE

Publication
EP 1386920 A4 20050914 (EN)

Application
EP 02720539 A 20020419

Priority
• JP 0203958 W 20020419
• JP 2001122057 A 20010420

Abstract (en)
[origin: EP1386920A1] This invention relates to benzimidazolone derivatives, represented by compounds of a general formula $\text{ÄIÜ} <\text{CHEM}> \text{Äin}$ which R<1> and R<2> stand for, e.g., hydrogen atoms; R<3a>, R<3b>, R<4>, R<5> stand for, e.g., hydrogen atoms and alkyl groups; R<6> stands for e.g., aryl or heteroaryl groups; A ring stands for 5- to 8-membered aliphatic heterocyclic ring containing one nitrogen atom; and Z stands for carbonyl group or sulfonyl group. The benzimidazolone derivatives of the invention exhibit antagonism to muscarinic acetylcholine receptors, and are useful as treating agent and/or prophylactic of Parkinson's disease; drug-induced parkinsonism, dystonia, akinesia, pancreatitis, bilestone/cholecystitis, biliary dyskinesia, achalasia, pain, itch, cholinergic urticaria, irritable bowel syndrome, vomiting, nausea, dizziness, Meniere's disease, motion sickness and urinary disturbance.

IPC 1-7
C07D 401/14; A61K 31/454; A61K 31/4545; A61K 31/497; A61K 31/55; A61P 1/00; A61P 1/08; A61P 1/16; A61P 1/18; A61P 13/00; A61P 17/00; A61P 17/04; A61P 25/04; A61P 25/14; A61P 25/16; A61P 43/00

IPC 8 full level
A61P 1/00 (2006.01); **A61P 1/08** (2006.01); **A61P 1/16** (2006.01); **A61P 1/18** (2006.01); **A61P 13/00** (2006.01); **A61P 17/00** (2006.01); **A61P 17/04** (2006.01); **A61P 25/04** (2006.01); **A61P 25/14** (2006.01); **A61P 25/16** (2006.01); **A61P 43/00** (2006.01); **C07D 401/14** (2006.01); **C07D 409/14** (2006.01)

CPC (source: EP US)
A61P 1/00 (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/08** (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 1/18** (2017.12 - EP); **A61P 11/08** (2017.12 - EP); **A61P 13/00** (2017.12 - EP); **A61P 13/02** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/04** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/14** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 401/14** (2013.01 - EP US); **C07D 409/14** (2013.01 - EP US)

Citation (search report)
• [A] WO 9724324 A1 19970710 - JANSSEN PHARMACEUTICA NV [BE], et al
• See references of WO 02085890A1

Cited by
JP2013515762A; EA023293B1; CN107074833A; EP3375781A4; US8344000B2; US7956069B2; US8288412B2; US8653071B2; US8049022B2; US8288413B2; WO2007130712A1; WO2008084300A1; WO2007142583A1; WO2011080751A3; WO2007036718A3; WO2007142585A1; US8067625B2; US8119661B2; US7135484B2; US8283364B2; US8541585B2; WO2008003446A3

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
EP 1386920 A1 20040204; **EP 1386920 A4 20050914**; CA 2444595 A1 20021031; JP WO2002085890 A1 20040812; US 2004147506 A1 20040729; US 7164024 B2 20070116; WO 02085890 A1 20021031

DOCDB simple family (application)
EP 02720539 A 20020419; CA 2444595 A 20020419; JP 0203958 W 20020419; JP 2002583417 A 20020419; US 47544703 A 20031020